MARCO and breast cancer: Previous studies indicate that downregulation of CXCL14 is associated with prognosis in gastric cancer patients [32], MT1X may aid in the prognostic discrimination of oral squamous cell carcinoma cases [33], and MARCO expression is associated with breast cancer survival and risk of recurrence [34].